Jacqueline's questions to SYNLOGIC (SYBX) leadership • Q3 2021
Question
Jacqueline from Oppenheimer asked if pediatric trials for SYNB1618 would run in parallel with the adult study, what the next steps for SYNB8802 would be after its proof-of-concept study, and whether SYNB1934 falls under the Ginkgo collaboration.
Answer
President and CEO Aoife Brennan confirmed the company sees a key opportunity in pediatrics and will pursue it upon receiving regulatory alignment. For SYNB8802, the next step would be to expand into other underlying etiologies to support a broad label, with the decision between a Phase 2 or Phase 2/3 study depending on the data. She clarified that SYNB1934 was developed using technology from Zymogen, predating the Ginkgo deal, and reminded that the Ginkgo collaboration involves an equity stake, not milestones or royalties.